Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | (R)-Fadrozole ((R)-CGS 16949A; FAD286) is a potent nonsteroidal inhibitor. (R)-Fadrozole also inhibits human placental aromatase (pIC 50 = 6.17) and aldosterone biosynthesis. (R)-Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats.. |
In vitro | The (-)-enantiomer with the S-absolute configuration is responsible for the high aromatase inhibitory activity of (R)-Fadrozole[1]. |
In vivo | Administration of (R)-fadrozole and (S)-fadrozole (0.24 and 1.2 mg/kg; daily; oral) consistently lowers plasma aldosterone levels. However, a reduction in the urinary aldosterone excretion rate was solely observed with (S)-fadrozole. Notably, (R)-fadrozole at the same dosages was effective in reducing preexisting left ventricular interstitial fibrosis by 50%, contrasting with canrenoate's 42% reduction. Unlike its isomer, (S)-fadrozole exhibited no antifibrotic effects. This study utilized SHHF rats, implementing a dosage regimen of 0.24 and 1.2 mg/kg administered orally on a daily basis, which led to decreased plasma aldosterone levels and a significant reversal of left ventricular interstitial fibrosis. |
Alias | FAD286, (R)-CGS 16949A free base, (R)-Fadrozole |
Molecular Weight | 223.27 |
Formula | C14H13N3 |
Cas No. | 102676-87-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.